A5041803353- Cutaneous lymphoproliferative disorders research
- Lymphoma Diagnosis and Treatment
- Nail Diseases and Treatments
- Fungal Infections and Studies
- Autoimmune Bullous Skin Diseases
- Chronic Lymphocytic Leukemia Research
- Cancer and Skin Lesions
- Systemic Lupus Erythematosus Research
- T-cell and Retrovirus Studies
- Immunodeficiency and Autoimmune Disorders
- Vascular Tumors and Angiosarcomas
- Contact Dermatitis and Allergies
- Autoimmune and Inflammatory Disorders
- CAR-T cell therapy research
- Hair Growth and Disorders
- Eosinophilic Disorders and Syndromes
- Inflammatory Myopathies and Dermatomyositis
- CNS Lymphoma Diagnosis and Treatment
- Drug-Induced Adverse Reactions
- Immune Cell Function and Interaction
- Healthcare Systems and Technology
- Parvovirus B19 Infection Studies
- Genetic and rare skin diseases.
- Skin Diseases and Diabetes
- Dermatology and Skin Diseases
Hospital Universitario Insular de Gran Canaria
2014-2025
Hospital de Basurto
2024
Hospital Central de la Cruz Roja San José y Santa Adela
2024
Hospital Universitario Virgen del Rocío
2024
Hospital de León
2024
Bellvitge University Hospital
2024
Research Institute Hospital 12 de Octubre
2024
Hospital Arnau de Vilanova
2024
Hospital Clínic de Barcelona
2024
Hospital de Cruces
2024
The value of dermatologists as consultants is increasing.To evaluate the activity inpatient consultants.Retrospective study consultations to Dermatology inpatients, visits per consultation, referral service, procedures performed, delay until visit and diagnoses based on ICD-9.3,144 requests generated 4,824 visits, 200 biopsies, 107 cultures other procedures. mean between request was 0.75 days. requesting service recorded in 3,097 cases: 21.5% by Internal Medicine, 11.4% Pediatrics, 8.3%...
Intravenous rituximab is a safe and effective option for the treatment of systemic non-Hodgkin B-cell lymphoma. The effectiveness intralesional (ILR) in primary cutaneous lymphomas (PCBL) has been described small number patients.To evaluate effectiveness, tolerance adverse effects ILR patients with follicle centre (FCL) marginal zone (MZL) PCBL.This was an epidemiological observational multicentre study PCBL treated ILR.Seventeen MZL 18 FCL were included. median lesions two per patient....
Abstract Background Advanced cutaneous T‐cell lymphomas (CTCL) are rare, generally refractory to therapeutic options, and have a poor prognosis. Haematopoietic stem cell transplantation (HSCT), mainly allogeneic HSCT (allo‐HSCT), is considered potentially curative option in CTCL other therapies. However, around half of patients relapse, allo‐HSCT associated with significant adverse events. The available evidence on the usefulness comes from isolated cases case series limited number patients....
Data regarding response to treatment in lymphomatoid papulosis (LyP) are scarce.To assess the daily clinical practice approach LyP and first-line treatments.This was a retrospective study enrolling 252 patients with LyP.Topical steroids, methotrexate phototherapy were most common treatments, prescribed for 35%, 20% 14% of patients, respectively. Complete (CR) achieved 48% treated patients. Eczematous lesions significantly increased relative risk (RR) not achieving CR (RR = 1.76; 95% CI...
Brentuximab vedotin (BV) has been approved for CD30-expressing cutaneous T-cell lymphoma (CTCL) after at least one previous systemic treatment. However, real clinical practice is still limited.To evaluate the response and tolerance of BV in a cohort patients with CTCL.We analysed CTCL treated from Spanish Primary Cutaneous Lymphoma Registry (RELCP).Sixty-seven were included. There 26 females mean age diagnosis was 59 years. Forty-eight mycosis fungoides (MF), 7 Sézary syndrome (SS) 12 CD30+...
Abstract: To analyze the care provided by consultant dermatologists to hospitalized pediatric patients, we retrospectively studied records of inpatient consultation requests received a hospital dermatology department between 2000 and 2009. The diagnoses were recorded according International Classification Diseases, Ninth Revision (ICD‐9). In high percentage cases, problem was addressed in single visit, few additional tests ordered. most common diagnostic groups diseases skin subcutaneous...
Primary cutaneous lymphomas are uncommon. This article describes the Cutaneous Lymphoma Registry of Spanish Academy Dermatology and Venereology (AEDV) reports on results from first year. Disease registry for patients with primary lymphoma. The participating hospitals prospectively recorded data diagnosis, treatment, tests, disease stage all A descriptive analysis was performed. In December 2017, contained 639 (60% male) 16 university hospitals. most common diagnoses, in order frequency, were...
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare cytotoxic cutaneous lymphoma. Differential diagnosis with lupus erythematosus panniculitis (LEP) can be challenging and overlapping cases have been described. In this study, we investigate whether gene expression profiling may or not identify markers that used to improve our understanding of the disease make precise differential diagnosis. SPTCL, LEP, were analyzed using customized NanoString platform including 208 genes...
Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) represents approximately 20% of B lymphomas with an intermediate prognosis. Spontaneous regression is uncommon; there are only 2 published cases. An 83-year-old woman presented orange erythematous nodules on the back her right elastic consistency, infiltrated, painful to touch, and 8-month evolution. A histological examination revealed a dense cellular dermo-hypodermic infiltrate sparing papillary dermis, composed cells...
Bexarotene has been approved to treat advanced stage cutaneous T-cell lymphomas (CTCL) since 1999. However, very few data have published on its long-term safety and efficacy profile. The aim of this study is determine the tolerability bexarotene outcomes by collecting 2nd largest case series date use vs CTCL.
Abstract Background Mycosis fungoides ( MF ) is the most common form of primary cutaneous T cell lymphoma. Psoralen combined with ultraviolet A PUVA a first‐line treatment for early‐stage disease. Objectives This study was conducted to assess clinical effectiveness and tolerance monotherapy in . Methods We retrospectively reviewed files patients who received stage I The included 31 patients, whom 32% presented Ia 67% Ib disease, 68% patch plaque All three times per week. Results Complete...
What is your diagnosis?
Abstract Background Reliable prognostic factors for patients with primary cutaneous anaplastic large cell lymphoma ( PCALCL ) are lacking. Objective To identify specific survival in . Methods Using the convenience sampling method, diagnosed from May 1986 to August 2017 16 University Departments were retrospectively reviewed. Results One hundred eight included (57 males). Median age at diagnosis was 58 years. All of them showed T1‐3N0M0 stages. Seventy per cent cases presented a solitary...
<h3>Importance</h3> Hypertriglyceridemia is the most frequent and limiting adverse effect of bexarotene therapy in cutaneous T-cell lymphoma (CTCL). Despite standard prophylactic measures, there a wide variability severity this complication, which could be associated with both genetic environmental factors. <h3>Objectives</h3> To analyze association between polymorphisms apolipoprotein genes<i>APOA5</i>,<i>APOC3</i>, and<i>APOE</i>and hypertriglyceridemia during to optimize patient selection...